Rexahn Pharma (RNN) Ticks Higher; Issues Encouraging Update on RX-21101 Preclinical Results Apr 21, 2014 10:41AM

Rexahn Pharmaceuticals, Inc. (AMEX: RNN) is trading strong today after the company announced promising preclinical results for RX-21101, the Company’s first development candidate derived from its Nano-Polymer-Drug Conjugate System (NPDCS) platform. Results of the study were presented in a poster titled, “Synthesis of targeted docetaxel-polymer conjugate and its anti-tumor efficacy,” at the American Association for Cancer Research (AACR) Annual Meeting 2014 held earlier this month.

The preclinical study was conducted by Rexahn in collaboration with the University of Maryland and Ohio State University, and evaluated the effect of RX-21101 in both in vitro human cancer cell lines and in vivo mice xenograft tumor models using human cancer cell lines. Results of the preclinical studies were the following:

RX-21101 showed complete tumor growth inhibition, enhanced tumor regression, and extended survival in mouse xenograft models without significant changes in body weight compared to intravenously administered docetaxel
The maximum tolerated dose of RX-21101 in mice was more than 150 mg/kg, which is much higher than that of free docetaxel (~25 mg/kg)
RX-21101 inhibited the proliferation of a variety of human cancer cells in the in vitro study
The high water solubility of RX-21101 eliminates the need of toxic co-solvents that are used with systemically administered docetaxel
This study demonstrated that RX-21101 is a promising anti-tumor development candidate with reduced toxicity and prolonged survival

“We are very encouraged by these preclinical findings, which showed that RX-21101 can inhibit tumor growth, increase tumor regression, and decrease the toxicity normally associated with a chemotherapeutic drug. Drug candidates developed on the NPDCS platform represent a clinical development approach for Rexahn with low risk, as we work to improve upon FDA approved anticancer compounds that are already widely used. We believe that our NPDCS platform could offer opportunities to co-develop and introduce new and improved versions of chemotherapeutic drugs that currently are, or are soon to become generic,” commented Rexahn’s CEO, Peter D. Suzdak, Ph.D.

Rexahn’s NPDCS platform combines existing chemotherapeutic agents with a proprietary polymer carrier that contains a targeting moiety which directs the drug directly into the tumor. This approach minimizes the levels of freely circulating anti-cancer agents in the body, which can reduce potential adverse events, and maximizes anti-tumor activities by accumulating the drug in the cancer tumor. NPDCS is a broad platform that has the potential to generate multiple development candidates for Rexahn going forward.

RX-21101 is a polymer conjugated form of docetaxel, a common chemotherapy agent that is now generic but is marketed worldwide under the trade name Taxotere® and had annual sales of $3.1 billion when still under patent. Docetaxel is used in the treatment of breast, ovarian, prostate, and non-small cell lung cancer.


Sonic Foundry (SOFO) Announces Partnership in China Apr 21, 2014 10:20AM

SONIC FDRY (NASDAQ: SOFO)
Sonic Foundry, Inc. (NASDAQ: SOFO) today disclosed a significant partnership in China with Beijing MC Technology, also known as Beijing OneZero.

Under the agreement Beijing OneZero will provide channel, reseller and installation services for Sonic Foundry’s Mediasite platform. In addition the company plans to develop integrated AV and IT solutions using Mediasite in the Chinese education sector.

Beijing OneZero is a leading value-added reseller of IT equipment into the Chinese government sector, with deep experience in the education and corporate markets.

“I am really pleased to enter this agreement with Sonic Foundry,” said Mr. Xin-Yang Sun, General Manager of Beijing OneZero. “The partnership with Sonic Foundry allows us to dramatically expand our offerings in the Chinese education system. I am proud to partner with them as we work together to realize a shared vision of anytime, anywhere education.”

“The stage is set for dramatic growth in video recorded lecture use during the next decade as the value chain of content providers and service platforms currently coming online matures. A best-in-class platform like Mediasite within a solution localized and supported by experienced partners in the market should be well-positioned to gain traction in this fast moving market,” said Stacy Austin-Li, analyst and China consultant, Wainhouse Research.

“With the significant growth of China’s education-technology market, we’re encouraged to reach a partnership that enables us to contribute to the country’s strategic development of educational offerings. Beijing OneZero is positioned to transform the Mediasite platform into real value for Chinese students, teachers and administrators at all levels of the education system,” said Gary Weis, CEO of Sonic Foundry.

Sonic Foundry saw a 43% growth in billings in Japan and a 25% growth in international billings overall in fiscal year 2013. The company recently announced a partnership in China with Neusoft, and acquired two international companies, Mediasite K.K. in Japan and MediaMission in the Netherlands.


Nokia (NOK) Sees Closing of Microsoft (MSFT) Deal on April 25th Apr 21, 2014 10:04AM

Nokia (NYSE: NOK) announced that it expects the transaction whereby the company will sell substantially all of its Devices & Services business to Microsoft (Nasdaq: MSFT) to close on April 25, 2014. The transaction is now subject only to certain customary closing conditions.

The transaction was originally announced on September 3, 2013.


Can-Fite BioPharma (CANF) Signs to Develop Commercial Biomarker Test for A3AR Apr 21, 2014 09:42AM

Can-Fite BioPharma Ltd. (AMEX: CANF) has signed an agreement with Smart Assays to develop a commercial biomarker blood test kit for the A3 adenosine receptor (A3AR). Can-Fite's A3AR predictive biomarker kit is designed for use at any molecular biology lab prior to treatment to help identify an individual patient's responsiveness to the Company's drugs, thus providing personalized medicine.

A3AR is present in high concentrations in inflammatory cells and cancer cells. Can-Fite's proprietary drugs target and bind to A3AR, causing cancer and inflammatory cell apoptosis (programmed cell death). This creates a targeted anti-cancer and anti-inflammatory effect, while leaving normal cells unharmed.

The U.S. Patent and Trademark Office recently issued Can-Fite a patent for the utilization of A3AR as a biomarker to predict patient response to its drug CF101 in autoimmune inflammatory indications. In December 2013, Can Fite reported favorable results from its Phase IIb rheumatoid arthritis clinical trial for CF101, an A3AR agonist. Only patients with elevated baseline expression levels of the biomarker A3AR were enrolled in the study. CF101 met all primary efficacy endpoints, showing statistically significant superiority over placebo in reducing signs and symptoms of rheumatoid arthritis.

"In our Phase IIa rheumatoid arthritis study we found that 70% of patients had high A3AR baseline levels. These patients were the most responsive to our drug. By developing a biomarker test that can be used at any molecular lab, we offer doctors and their patients a simple method for determining which patients will benefit most from CF101. Because rheumatoid arthritis is a complex disease with a high degree of clinical heterogeneity, a personalized medicine approach is needed and CF101 coupled with a biomarker test is designed to meet this need," stated Can-Fite CEO Dr. Pnina Fishman.

Smart Assays, led by Dr. Raphael Mayer, is a company that specializes in the design of biomarker assays for diagnosis, prediction and disease status follow up.


Vimicro International Corporation (VIMC) Signs Agreement on SVAC-Compliant Chips Apr 21, 2014 09:16AM

Vimicro International Corporation (NASDAQ: VIMC) ("Vimicro" or the "Company"), a leading video processing IC and surveillance solution provider, today announced that the Company signed an agreement regarding SVAC-compliant chips with the First Research Institute of the Ministry of Public Security. The signing ceremony was held on April 18 in Beijing and was attended by: Party Secretary Mr. Wang Gang, Director Mr. Qiu Baoli, Deputy Director Ms. Chen Zhaowu, etc. of the First Research Institute of Ministry of Public Security; Vimicro's CEO, Dr. Zhonghan (John) Deng, and the President Mr. Zhaowei (Kevin) Jin.

The SVAC (Surveillance Video and Audio Coding) surveillance standard represents one of the most important achievements in the field of security and surveillance monitoring and it is the only codec specifically designed for security surveillance needs. SVAC was promulgated in 2011 as a national standard, and it was initiated and co-developed by the First Research Institute of the Ministry of Public Security and Vimicro, under the leadership of the Ministry of Public Security and the Ministry of Industry and Information Technology, with the goal of ensuring national safety and security. To-date, SVAC has been implemented in Shanxi and Hebei provinces and in other regions to provide public security, urban management, and in other large-scale industrial applications. Recently, the Ministry of Public Security selected Guangdong Province as the first province for a national SVAC standard demonstration running through October 2014, along with video collection points funded by Guangdong provincial government, which together will comprise a uniform implementation of the SVAC national standard.

With SVAC's mature technology and increasing recognition, the total surveillance market is at approximately 300 billion Yuan (approximately USD $50 million) in 2012 and is estimated to be growing at an annual growth rate of approximately 20%. The close cooperation between Vimicro and First Research Institute of the Ministry of Public Security will continue to develop future SVAC national standards with the respect to core chips, safety programs, promotions, and other system features, which will benefit from both parties' common resources, common strengths, and the promotion of development of future SVAC-compliant products, as well as system applications and industrial processes using video surveillance. Moreover, SVAC sets an example for the cooperation between government and industry on the development of national standards, the promotion of domestic high-tech industries, and the achievement of major successes.


More Corporate News

View Older Stories

Apr 21, 2014 08:57AM Impax Laboratories (IPXL) Names G. Frederick Wilkinson President and CEO
Apr 21, 2014 08:33AM Cubist Pharma (CBST) Submits Ceftolozane/Tazobactam NDA to U.S. FDA
Apr 21, 2014 08:15AM Yingli (YGE) to Cooperate with Local Module Manufacturer in France
Apr 21, 2014 08:08AM Interxion (INXN) to Accerate Construction of AMS 7, FRA 8 Data Centers; Increases CapEx Outlook
Apr 21, 2014 08:07AM Ampio Pharma (AMPE) Unit, Vyrix Pharma, Files for IPO (VYRX)
Apr 21, 2014 07:59AM Microsoft (MSFT) Comments on Office 365 Launch in China
Apr 21, 2014 07:53AM Leidos Holdings (LDOS) Receives Contract from NATO NSPA for NFMS Management
Apr 21, 2014 07:37AM ChinaNet Online Holdings, Inc (CNET) Falls Out of Compliance with Nasdaq Listing Rules
Apr 21, 2014 07:19AM Orthofix (OFIX) CFO Buxton Resigns; Appointee Named
Apr 21, 2014 07:14AM Dominos Pizza (DPZ) Integrates Google Wallet into Android App (GOOG)
Apr 21, 2014 07:13AM Nu Skin China to Accept Applications for Sales People Starting May 1st (NUS)
Apr 21, 2014 07:12AM Tesla Motors (TSLA) Will Release Q1 Results on May 7th; Street Sees Flat EPS Growth
Apr 21, 2014 06:57AM Sarepta (SRPT) Plans to Submit NDA for Eteplirsen by End of 2014
Apr 21, 2014 06:49AM 3D Systems (DDD) Affirms Dismissal of DSM Desotech Suit
Apr 17, 2014 05:14PM UPDATE: Avago Tech (AVGO) Active Following Patent Case Ruling
Apr 17, 2014 05:14PM UPDATE: Avago Tech (AVGO) Active Following Patent Case Ruling
Apr 17, 2014 05:07PM Spectrum Pharmaceuticals (SPPI) Appointed Joseph Turgeon as President and COO
Apr 17, 2014 05:01PM Amkor Technology (AMKR) Issues Equity in $56.4M Convertible Notes Conversion
Apr 17, 2014 05:00PM Catalyst Pharma (CPRX), BioMarin (BMRN) Enter Amended Licensing Agreement
Apr 17, 2014 04:57PM Interactive Intelligence (ININ) Signs LOI to Acquire OrgSpan
Apr 17, 2014 04:54PM Amazon.com, Inc. (AMZN) Bolsters Fire TV Voice Search with New Offerings
Apr 17, 2014 04:30PM Dynagas LNG Partners (DLNG) Announces New 13-Year Time-Charter Contract
Apr 17, 2014 04:26PM Lionsgate (LGF) to Integrate Marketing Ops with Summit Film Labels
Apr 17, 2014 04:25PM Keurig Green Mountain (GMCR) Closes 1.41M Common Stock SPA with Luigi Lavazza
Apr 17, 2014 04:17PM Actavis (ACT) to Acquire Products from Akorn (AKRX)
Apr 17, 2014 04:14PM Allegheny Technologies (ATI) to Close Iron Castings Business
Apr 17, 2014 04:06PM Actavis (ACT), Forest Labs (FRX) Report Receipt of Second Info Request Under HSR Act
Apr 17, 2014 04:02PM Amazon (AMZN) Fire TV Gets New Partners in Voice Search
Apr 17, 2014 03:56PM GSK (GSK) and Genmab Receive FDA Approval for Wider Use of Arzerra
Apr 17, 2014 03:39PM Hawaiian Airlines (HA) Enters Code Share Agreement With Air China
Apr 17, 2014 02:06PM UPDATE: Arch Coal (ACI) Probed on Potential Misconduct - Bloomberg
Apr 17, 2014 02:06PM UPDATE: Arch Coal (ACI) Probed on Potential Misconduct - Bloomberg
Apr 17, 2014 01:10PM MasterCard (MA) Board Recommends Two New Candidates
Apr 17, 2014 11:25AM OPKO Health (OPK) to Acquire Inspiro Medical
Apr 17, 2014 11:01AM LiveDeal Inc. (LIVE) Moves Higher on Positive PR
Apr 17, 2014 10:41AM UPDATE: MoneyGram (MGI), XOOM (XOOM) on Watch After Wal-Mart Signs New Money Transfer Agreement
Apr 17, 2014 10:22AM AuRico Gold (AUQ) Board Adopts Advance Notice By-Law Connected to Director Nominations
Apr 17, 2014 10:21AM Galectin (GALT) Says 1st Patient Dosed in Second Ph-1 Trial of GR-MD-02 for NASH
Apr 17, 2014 10:16AM Vintage Capital Sends Letter to Aaron's (AAN)
Apr 17, 2014 09:12AM Aspen Insurance Holdings Ltd. (AHL) Adopts 'Poison Pill' Provision
Apr 17, 2014 10:41AM UPDATE: MoneyGram (MGI), XOOM (XOOM) on Watch After Wal-Mart Signs New Money Transfer Agreement
Apr 17, 2014 09:01AM Thor Industries, Inc. (THO) Acquires K-Z, Inc., in $53.4M Cash Deal
Apr 17, 2014 08:55AM Wal-mart (WMT), Ria (EEFT) Debut Money-Transfer Service
Apr 17, 2014 08:44AM Teva Pharma (TEVA), Pfizer (PFE) Settle Over Generic Celebrex
Apr 17, 2014 08:38AM GT Advanced Technologies (GTAT) Will Report Q1 Results May 7th; Street Sees Wider Loss
Apr 17, 2014 08:05AM Nokia (NOK) Warns on AC-300 Charger in Europe, the U.K.; Used Mainly on Lumia 2520 Tablet
Apr 17, 2014 07:05AM McDermott (MDR) Signs for Exclusive Right to Operate Spoolbase in North Sea
Apr 16, 2014 05:56PM Yahoo! (YHOO) Nominates Three New Board Members
Apr 16, 2014 05:38PM UPDATE: Sandisk Corp (SNDK) Boosts FY Margin Guidance
View Older Stories